Chinese Phase 3 Trial of Roxadustat in Non-Myeloid Malignancies Meets Primary End Point
Roxadustat proved to be noninferior to recombinant erythropoietin alfa with regard to change in hemoglobin level from baseline to an average level during weeks 9 to 13 in patients receiving concurrent chemotherapy for non-myeloid malignancies in China, meeting the primary end point of an ongoing phase 3 trial.
Source: onclive.com